NNVC
NanoViricides, Inc.
Price Chart
Latest Quote
$1.31
-0.01 (-0.76%)
Current Price
| Previous Close | $1.32 |
| Open | $1.29 |
| Day High | $1.37 |
| Day Low | $1.26 |
| Volume | 192,778 |
Stock Information
| Shares Outstanding | 22.98M |
| Cash Equivalents | $3.21M |
| Net Income | $-8.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $30.11M |
| EPS (TTM) | $-0.44 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $25.14M |
| Income | $-8.09M |
| Book/sh | $0.42 |
| Cash/sh | $0.14 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 3.02 |
| Current Ratio | 3.17 |
Returns & Margins
| ROA | -50.47% |
| ROE | -89.97% |
Ownership
| Insider Ownership | 2.64% |
| Institutional Ownership | 8.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.74 |
| P/B | 3.10 |
Analyst Data
| Recommendation | none |
| Target Price | $6.00 |
Technical Indicators
| SMA20 | $1.47 |
| SMA50 | $1.42 |
| SMA200 | $1.29 |
| RSI | 35.11 |
| ATR | 0.1236 |
| Shares Float | 21.08M |
| Short Float | 7.46% |
| Short Ratio | 0.84 |
| Volatility | 1.64 |
| Rel Volume | 0.09 |
Performance History
| Week | -7.09% |
| Month | -15.48% |
| Quarter | +33.67% |
| 6 Months | +8.26% |
| YTD | +8.26% |
| Year | -8.39% |
| 3 Years | +20.18% |
| 5 Years | -67.73% |
| 10 Years | -95.77% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.31 | 192,778 |
| 2026-06-22 | $1.32 | 850,600 |
| 2026-06-18 | $1.40 | 262,200 |
| 2026-06-17 | $1.34 | 119,800 |
| 2026-06-16 | $1.36 | 387,000 |
| 2026-06-15 | $1.41 | 634,700 |
| 2026-06-12 | $1.22 | 422,600 |
| 2026-06-11 | $1.37 | 160,500 |
| 2026-06-10 | $1.34 | 329,700 |
| 2026-06-09 | $1.40 | 282,200 |
| 2026-06-08 | $1.43 | 505,500 |
| 2026-06-05 | $1.38 | 682,900 |
| 2026-06-04 | $1.50 | 234,800 |
| 2026-06-03 | $1.51 | 419,800 |
| 2026-06-02 | $1.59 | 448,100 |
| 2026-06-01 | $1.68 | 645,000 |
| 2026-05-29 | $1.78 | 1,097,100 |
| 2026-05-28 | $1.86 | 2,849,000 |
| 2026-05-27 | $1.75 | 28,930,000 |
| 2026-05-26 | $1.51 | 1,154,400 |
About NanoViricides, Inc.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
đ° Latest News
NanoViricides closes $2M direct offering
Proactive âĸ 2026-05-19T13:06:00Z
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
Proactive âĸ 2026-05-18T12:34:00Z
NanoViricides to raise $2M in registered direct offering
Proactive âĸ 2026-05-15T14:02:00Z
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
Exec Edge âĸ 2026-05-12T12:35:06Z
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak
Proactive âĸ 2026-05-11T13:00:00Z
NanoViricides to Participate at D. Boral Capital Global Conference in NYC
Exec Edge âĸ 2026-05-07T12:35:07Z
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment
Insider Monkey âĸ 2026-05-07T12:30:58Z
NanoViricidesâ Measles Treatment Granted Orphan Drug Designation by FDA
Exec Edge âĸ 2026-05-06T12:35:33Z
NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment
Proactive âĸ 2026-05-04T13:00:00Z
NanoViricides says NV-387 could address measles outbreaks as cases rise globally
Proactive âĸ 2026-04-21T13:10:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $149 | $49,808 | $938 | $5,123 |
| Total Expenses | $9,591,645 | $8,516,111 | $8,943,468 | $8,113,599 |
| Net Non Operating Interest Income Expense | $124,679 | $221,965 | $354,895 | $6,736 |
| Interest Expense Non Operating | $149 | $49,808 | $938 | $5,123 |
| Operating Expense | $9,591,645 | $8,516,111 | $8,943,468 | $8,113,599 |
| General And Administrative Expense | $4,042,544 | $3,078,814 | $2,551,054 | $2,328,737 |
| Other Income Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Net Interest Income | $124,679 | $221,965 | $354,895 | $6,736 |
| Interest Income | $124,828 | $271,773 | $355,833 | $11,859 |
| Normalized Income | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Net Income From Continuing And Discontinued Operation | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Total Operating Income As Reported | $-9,591,645 | $-8,516,111 | $-8,943,468 | $-8,113,599 |
| Net Income Common Stockholders | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Net Income | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Net Income Including Noncontrolling Interests | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Net Income Continuous Operations | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Pretax Income | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Interest Income Non Operating | $124,828 | $271,773 | $355,833 | $11,859 |
| Operating Income | $-9,591,645 | $-8,516,111 | $-8,943,468 | $-8,113,599 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.63 | $-0.70 | $-0.74 | $-0.70 |
| Basic EPS | $-0.63 | $-0.70 | $-0.74 | $-0.70 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,723,012 | $-7,485,324 | $-7,840,106 | $-7,378,415 |
| Reconciled Depreciation | $743,805 | $759,014 | $747,529 | $723,325 |
| EBITDA (Bullshit earnings) | $-8,723,012 | $-7,485,324 | $-7,840,106 | $-7,378,415 |
| EBIT | $-9,466,817 | $-8,244,338 | $-8,587,635 | $-8,101,740 |
| Diluted Average Shares | $15,116,548 | $11,871,054 | $11,626,220 | $11,534,698 |
| Basic Average Shares | $15,116,548 | $11,871,054 | $11,626,220 | $11,534,698 |
| Diluted NI Availto Com Stockholders | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Research And Development | $5,549,101 | $5,437,297 | $6,392,414 | $5,784,862 |
| Selling General And Administration | $4,042,544 | $3,078,814 | $2,551,054 | $2,328,737 |
| Other Gand A | $4,042,544 | $3,078,814 | $2,551,054 | $2,328,737 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
| Tax Provision | - | - | - | $0 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,200,527 | $11,138,769 | $14,532,052 | $22,740,177 |
| Total Assets | $8,824,085 | $12,822,853 | $16,899,880 | $23,494,862 |
| Total Non Current Assets | $7,153,375 | $7,852,333 | $8,454,586 | $9,078,482 |
| Other Non Current Assets | $2,445 | $14,562 | $14,361 | $38,925 |
| Goodwill And Other Intangible Assets | $317,039 | $325,308 | $333,578 | $341,848 |
| Other Intangible Assets | $317,039 | $325,308 | $333,578 | $341,848 |
| Current Assets | $1,670,710 | $4,970,520 | $8,445,294 | $14,416,380 |
| Prepaid Assets | $112,146 | $172,742 | $295,486 | $350,021 |
| Cash Cash Equivalents And Short Term Investments | $1,558,564 | $4,797,778 | $8,149,808 | $14,066,359 |
| Cash And Cash Equivalents | $1,558,564 | $4,797,778 | $8,149,808 | $14,066,359 |
| Non Current Prepaid Assets | - | - | $0 | $3,515 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | $94,788 |
| Current Debt And Capital Lease Obligation | - | - | - | $94,788 |
| Current Debt | - | - | - | $94,788 |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,306,519 | $1,358,776 | $2,034,250 | $412,837 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $1,500,000 | $0 |
| Current Liabilities | $1,306,519 | $1,358,776 | $534,250 | $412,837 |
| Payables And Accrued Expenses | $1,280,550 | $1,335,244 | $495,190 | $279,373 |
| Payables | $1,280,550 | $1,096,309 | $390,490 | $272,357 |
| Accounts Payable | $1,280,550 | $1,096,309 | $390,490 | $57,960 |
| Tradeand Other Payables Non Current | - | $0 | $0 | - |
| Other Non Current Liabilities | - | - | $1,500,000 | - |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $7,517,557 | $11,464,068 | $14,865,625 | $23,082,020 |
| Preferred Stock Equity | $9 | $9 | $5 | $5 |
| Total Equity Gross Minority Interest | $7,517,566 | $11,464,077 | $14,865,630 | $23,082,025 |
| Stockholders Equity | $7,517,566 | $11,464,077 | $14,865,630 | $23,082,025 |
| Retained Earnings | $-148,841,861 | $-139,374,895 | $-131,080,749 | $-122,492,176 |
| Other | ||||
| Ordinary Shares Number | $16,606,832 | $13,144,055 | $11,698,497 | $11,592,173 |
| Share Issued | $16,606,832 | $13,144,055 | $11,698,497 | $11,592,173 |
| Tangible Book Value | $7,200,518 | $11,138,760 | $14,532,047 | $22,740,172 |
| Invested Capital | $7,517,557 | $11,464,068 | $14,865,625 | $23,176,808 |
| Working Capital | $364,191 | $3,611,744 | $7,911,044 | $14,003,543 |
| Total Capitalization | $7,517,566 | $11,464,077 | $14,865,630 | $23,082,025 |
| Additional Paid In Capital | $156,359,252 | $150,838,832 | $145,946,257 | $145,574,080 |
| Capital Stock | $175 | $140 | $122 | $121 |
| Common Stock | $166 | $131 | $117 | $116 |
| Preferred Stock | $9 | $9 | $5 | $5 |
| Pensionand Other Post Retirement Benefit Plans Current | $25,969 | $23,532 | $39,060 | $38,676 |
| Current Accrued Expenses | $0 | $238,935 | $104,700 | $7,016 |
| Net PPE | $6,833,891 | $7,512,463 | $8,106,647 | $8,694,194 |
| Accumulated Depreciation | $-8,189,359 | $-7,453,823 | $-6,703,079 | $-5,963,820 |
| Gross PPE | $15,023,250 | $14,966,286 | $14,809,726 | $14,658,014 |
| Other Properties | $6,512,173 | $6,469,578 | $6,315,727 | $6,185,210 |
| Machinery Furniture Equipment | $8,251,077 | $8,236,708 | $8,233,999 | $8,212,804 |
| Land And Improvements | $260,000 | $260,000 | $260,000 | $260,000 |
| Properties | $0 | $0 | $0 | $0 |
| Preferred Shares Number | - | $903,216 | - | - |
| Dueto Related Parties Non Current | - | $0 | $1,500,000 | - |
| Dueto Related Parties Current | - | $720,039 | $233,434 | $214,397 |
| Line Of Credit | - | - | $0 | $94,788 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,535,643 | $-6,472,067 | $-5,821,763 | $-6,215,602 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,478,679 | $-6,315,507 | $-5,670,051 | $-5,891,254 |
| Cash Flow From Continuing Operating Activities | $-8,478,679 | $-6,315,507 | $-5,670,051 | $-5,891,254 |
| Operating Gains Losses | $679 | $563 | $1,012 | $4,215 |
| Investing Activities | ||||
| Capital Expenditure | $-56,964 | $-156,560 | $-151,712 | $-324,348 |
| Investing Cash Flow | $-56,964 | $-156,560 | $-151,712 | $-324,348 |
| Cash Flow From Continuing Investing Activities | $-56,964 | $-156,560 | $-151,712 | $-324,348 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,296,429 | $3,120,037 | $0 | $0 |
| Financing Cash Flow | $5,296,429 | $3,120,037 | $-94,788 | $-234,716 |
| Cash Flow From Continuing Financing Activities | $5,296,429 | $3,120,037 | $-94,788 | $-234,716 |
| Net Common Stock Issuance | $5,296,429 | $3,120,037 | $0 | $0 |
| Common Stock Issuance | $5,296,429 | $3,120,037 | $0 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $149 | $0 | $938 | $5,123 |
| End Cash Position | $1,558,564 | $4,797,778 | $8,149,808 | $14,066,359 |
| Beginning Cash Position | $4,797,778 | $8,149,808 | $14,066,359 | $20,516,677 |
| Changes In Cash | $-3,239,214 | $-3,352,030 | $-5,916,551 | $-6,450,318 |
| Net PPE Purchase And Sale | $-56,964 | $-156,560 | $-151,712 | $-324,348 |
| Purchase Of PPE | $-56,964 | $-156,560 | $-151,712 | $-324,348 |
| Change In Working Capital | $20,456 | $996,877 | $1,798,815 | $214,563 |
| Change In Other Current Assets | $12,117 | $-201 | $28,079 | $-38,925 |
| Change In Payables And Accrued Expense | $-52,257 | $874,334 | $216,201 | $62,209 |
| Change In Accrued Expense | $-236,498 | $168,516 | $98,068 | $21,407 |
| Change In Payable | $184,241 | $705,818 | $118,133 | $40,802 |
| Change In Account Payable | $184,241 | $705,818 | $118,133 | $40,802 |
| Change In Prepaid Assets | $60,596 | $122,744 | $54,535 | $191,279 |
| Stock Based Compensation | $223,347 | $222,185 | $214,179 | $338,418 |
| Depreciation Amortization Depletion | $743,805 | $759,014 | $747,529 | $723,325 |
| Depreciation And Amortization | $743,805 | $759,014 | $747,529 | $723,325 |
| Amortization Cash Flow | $8,269 | $8,270 | $8,270 | $8,270 |
| Amortization Of Intangibles | $8,269 | $8,270 | $8,270 | $8,270 |
| Depreciation | $735,536 | $750,744 | $739,259 | $715,055 |
| Gain Loss On Investment Securities | $679 | $563 | $1,012 | $4,215 |
| Net Income From Continuing Operations | $-9,466,966 | $-8,294,146 | $-8,588,573 | $-8,106,863 |
| Repayment Of Debt | - | $0 | $-94,788 | $-234,716 |
| Net Issuance Payments Of Debt | - | $0 | $-94,788 | $-234,716 |
| Net Long Term Debt Issuance | - | $0 | $-94,788 | $0 |
| Long Term Debt Payments | - | $0 | $-94,788 | $0 |
| Change In Other Current Liabilities | - | $0 | $1,500,000 | $0 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | $-94,788 | $-234,716 |
| Short Term Debt Payments | - | - | $-94,788 | $-234,716 |
| Other Non Cash Items | - | - | $156,987 | $935,088 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-21